Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALPG | P10696 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5097616 | 0.85 | TACR2 (0.44) | BTKALDH1A1USP30SMN1; SMN2HPGD | |
| SCHEMBL6810535 | 0.77 | KMT2A (0.40) | ALDH1A1SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL6604451 | 0.75 | CTSS (0.44) | USP30KMT2A | |
| SCHEMBL13326644 | 0.75 | USP30 (0.60) | ALDH1A1USP30KMT2ALMNA | |
| SCHEMBL5105424 | 0.74 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2HPGDLMNA | |
| SCHEMBL13326733 | 0.72 | KMT2A (0.60) | ALDH1A1EPHX1SMN1; SMN2HPGDKMT2A | |
| SCHEMBL5105626 | 0.72 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2HPGDKMT2A | |
| SCHEMBL5097938 | 0.72 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2HPGDKMT2ALMNA | |
| SCHEMBL13326532 | 0.70 | KDM4E (0.60) | ALDH1A1GPR119KMT2ALMNA | |
| SCHEMBL5439243 | 0.69 | CTSK (0.58) | USP30SMN1; SMN2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342027-B2 | 1-phenylpiperidin-3-one derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2008-03-11 | — | — | US | disclosed |
| US-20050234057-A1 | 1-Phenylpiperidin-3-one derivatives and processes for the preparation thereof | DONG-A PHARMACEUTICAL CO., LTD. (KR) | 2005-10-20 | — | — | US | disclosed |
| WO-2004011457-A1 | 1-PHENYLPIPERIDIN-3-ONE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234057-A1 | 1-Phenylpiperidin-3-one derivatives and processes for the preparation thereof | CTRL, PRCP, CLPP | BTK 2660/4885ALDH1A1 740/4885EPHX1 1720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.